<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02698410</url>
  </required_header>
  <id_info>
    <org_study_id>A-93-52030-325</org_study_id>
    <secondary_id>2014-005579-10</secondary_id>
    <nct_id>NCT02698410</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.</brief_title>
  <acronym>ATLANT</acronym>
  <official_title>Efficacy and Safety of Lanreotide ATG 120 mg in Combination With Temozolomide in Subjects With Progressive Well Differentiated Thoracic Neuroendocrine Tumors. A Phase II, Multicentre, Single Arm, Open-label Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the protocol is to evaluate the efficacy and safety of Lanreotide ATG 120 mg
      in combination with Temozolomide in subjects with unresectable advanced neuroendocrine
      tumours of the lung or thymus as Disease Control Rate at 9 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response of subjects to the study combination therapy</measure>
    <time_frame>9 months</time_frame>
    <description>Responders are subjects showing disease control rate (DCR) according to RECIST criteria v 1.1, defined as objective response or stability of the disease. They include: CR (complete response), PR (partial response) or SD (stable disease)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From randomisation up to 52 weeks</time_frame>
    <description>Defined as the time from the first treatment administration until progression according to RECIST criteria v 1.1 or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>From randomisation up to 52 weeks</time_frame>
    <description>Defined as the time from the first treatment administration to the first objective tumor response (PR or CR) according to RECIST criteria v 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From randomisation up to 52 weeks</time_frame>
    <description>Defined as the time from onset of the first objective tumor response (PR or CR) to objective tumor progression (PD, according to RECIST criteria v 1.1) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>From randomisation up to 52 weeks</time_frame>
    <description>Defined as the time from the first treatment administration to the first objective tumor progression (PD) observed according to RECIST criteria v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall response according to RECIST criteria v 1.1 (CR, PR, SD, PD)</measure>
    <time_frame>Baseline, week 12, 24, 36, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) according to RECIST criteria v 1.1 (CR, PR)</measure>
    <time_frame>Baseline, week 12, 24, 36, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) according to RECIST criteria v 1.1 (CR, PR, SD)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Response according to decrease in CgA plasma level in subject with baseline CgA level greater than the upper limit of normal (ULN).</measure>
    <time_frame>Baseline, week 4, 12, 24, 36 and end of study visit (up to 52 weeks)</time_frame>
    <description>Biochemical objective response is defined as a decrease of CgA ≥ 50%, while stable disease as a decrease ≥ 25% and less than 50%, as their best response to study treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of Neuron-Specific Enolase (NSE) and Chromogranin A (CgA) biomarkers</measure>
    <time_frame>Week 2, 4, 12, 24, 36, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker expression correlated to tumor response for PFS, ORR, and DCR</measure>
    <time_frame>9 and 12 months</time_frame>
    <description>Immunohistochemistry assay Human Somatostatin Receptors 2 (SSTR2), Ki67 and O6-methylguanine-DNA methyltransferase (MGMT) status in tissue obtained from paraffin embedded primary tumor surgery specimens or biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor radiological response</measure>
    <time_frame>End of study (up to week 52)</time_frame>
    <description>Central and local assessment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neuroendocrine Tumours</condition>
  <arm_group>
    <arm_group_label>Lanreotide (Autogel formulation) and Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lanreotide ATG 120 mg every 28 days, deep subcutaneous injection for a maximum of 48 weeks, for a total number of 12 injections.
Temozolomide 250 mg hard capsules, for 5 consecutive days every 28 days, oral route, for a maximum of 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide (Autogel formulation) and Temozolomide</intervention_name>
    <arm_group_label>Lanreotide (Autogel formulation) and Temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological documented unresectable advanced (locally or metastatic) well or
             moderately differentiated neuroendocrine tumors of the lung or thymus (typical and
             atypical carcinoids according to the World Health Organisation (WHO) 2004 criteria);

          -  Imaging documented progression within 12 months before screening visit (V1), according
             to RECIST criteria v 1.1;

          -  Measurable disease, as defined by RECIST criteria v 1.1, on a CT scan performed at
             screening visit (V1);

          -  Octreoscan or Ga68-DOTA-TATE/TOC/NOC-PET-TC within 12 months before screening visit
             (V1);

          -  Adequate liver, renal and bone marrow function.

        Exclusion Criteria:

          -  Poorly differentiated neuroendocrine carcinoma and mixed Neuroendocrine tumours (NET),
             according to WHO 2004 criteria.

          -  Neuroendocrine tumours other than lung or thymus.

          -  Non-neuroendocrine thymic neoplasm.

          -  Treated with systemic therapies (chemotherapy, interferon-alpha, somatostatin
             analogues, molecular target therapies) within 1 month prior to screening visit (V1).

          -  Treated with a number of systemic therapy lines &gt; 3 prior to screening visit (V1), and
             any of the following:

               1. for chemotherapy no more than 1 line prior to V1;

               2. for somatostatin analogue no more than 1 line therapy, considered as treatment
                  lasting more than 6 months, prior to V1;

               3. no therapy with Temozolomide (TMZ) prior to V1. Received a prior therapy with
                  Peptide Receptor Radionuclide Therapy (PRRT) within 6 months prior to screening
                  visit (V1).

          -  Received locoregional therapies (Transarterial embolization, Transcatheter arterial
             chemoembolization, thermo-ablation with radio-frequency) and Selective internal
             radiotherapy within 3 months prior to screening visit (V1).

          -  Presence of symptomatic brain metastasis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paola Mazzanti, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ipsen Recruitment Enquiries</last_name>
    <email>clinical.trials@ipsen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncologia Medica - Istituto Oncologico del Mediterraneo - IOM</name>
      <address>
        <city>Viagrande</city>
        <state>Catania</state>
        <zip>95029</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Oncologia Medica Policlinico San Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Oncologia Azienda Ospedaliera Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica - A.S.L. Brindisi - Presidio Ospedaliero Senatore Antonio Perrino</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Medica - Presidio Ospedaliero Businco</name>
      <address>
        <city>Cagliari</city>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l., IRCCS</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unità Oncologia Medica Gastrointestinale e Tumori Neuroendocrini Istituto Europeo di Oncologia, IEO</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica , Università degli Studi</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Università di Torino Ospedale San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.O.C. di oncologia Medica - Dipartimento di Oncologia Policlinico Universitario P. Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>S.C di Oncologia Medica, Azienda Ospedaliera Universitaria di Perugia</name>
      <address>
        <city>Perugia</city>
        <zip>06123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia - Azienda Ospedaliero-Universitaria Pisana Ospedale S. Chiara</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica - Istituto Tumori Regina Elena San Gallicano</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OUC di Oncologia- Azienda Ospedaliera Universitaria Integrata - Ospedale Borgo Roma</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2016</study_first_submitted>
  <study_first_submitted_qc>February 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

